TScan Therapeutics (TCRX) EBITDA Margin (2020 - 2026)

TScan Therapeutics (TCRX) has reported EBITDA Margin for 7 consecutive years, with 2901.33% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA Margin fell 164473.0% year-over-year to 2901.33% in Q2 2026; TTM through Jun 2026 was 1695.15%, a 37692.0% increase from a year earlier, with the FY2025 full-year figure at 1315.38%, up 347230.0% from the prior year.
• EBITDA Margin was 2901.33% for Q2 2026 at TScan Therapeutics, up from 2967.31% in the prior quarter.
• Over five years, EBITDA Margin peaked at 296.17% in Q4 2023 and troughed at 6364.55% in Q2 2024.
• A 5-year average of 1988.51% and a median of 1093.01% in 2025 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin plunged 558279 bps in 2024 and jumped 510795 bps in 2025, its largest moves.
• Over 5 years, EBITDA Margin stood at 602.55% in 2022, then jumped by 51 bps to 296.17% in 2023, then plunged by 1764 bps to 5520.6% in 2024, then surged by 83 bps to 929.41% in 2025, then plunged by 212 bps to 2901.33% in 2026.
• The last three EBITDA Margin figures came in at 2901.33% (Q2 2026), 2967.31% (Q1 2026), and 929.41% (Q4 2025), per Business Quant data.